Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedHH
HBM Healthcare Investments
Activity from announced rounds
Activity in this selectionOct 10, 2026 · Jul 13, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $130M 1 disclosed · full round size, not this investor’s share